Bilirubin coating attenuates the inflammatory response to everolimus‐coated stents
Authors:
- 10 July 2017
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 106 (4) , 1486-1495
Abstract
The aim of this study was to evaluate the effects of bilirubin‐ and/or everolimus (EVL)‐coated stents to prevent arterial neointimal hyperplasia and inflammation in vitro and in vivo. The stents were prepared by spray coating bare metal stents (BMS) with bilirubin and/or EVL. Study groups were divided into (1) BMS, (2) bilirubin‐coated stents (BES), (3) commercialized stents (Synergy™; EES), and (4) bilirubin/EVL‐coated stents (B‐EES). The coating thickness and drug release rates were comparable to previous reports (i.e., n = 10, p < 0.05). Stents were randomly implanted to 40 coronary arteries in 20 pigs and subjected to various analyses after 4 weeks of implantation. As results, the inflammation score was dramatically increased in the EES group (2.1 ± 0.42) compared to that of the other groups (1.5 ± 0.55, 1.3 ± 0.23, and 1.5 ± 0.27 for BMS, BES, and B‐EES, respectively, n = 10, p < 0.05). Immunofluorescence analysis revealed that inflammation was prevented in the bilirubin‐containing groups (BES and B‐EES). However, the percent area of restenosis was decreased in the EVL‐containing groups (20.5 ± 4.11% for EES and 18.4 ± 3.61% for B‐EES) compared to the non‐EVL‐containing groups (32.3 ± 6.41% for BMS and 29.6 ± 5.95% for BES, n = 10, p < 0.05). The percent areas of restenosis determined by histopathology, optical coherence tomography, and micro‐computed tomography were consistent. In addition, the stent was barely covered in the EES and B‐EES groups at 4 weeks postimplantation. These dual drug‐coated stents may be especially beneficial to patients who have an increased risk of inflammation. These stents have great potential for use in cardiovascular applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1486–1495, 2018.Keywords
Funding Information
- Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1527)
- National Research Foundation of Korea (NRF), Ministry of Science, ICT & Future Planning (2014R1A1A1005948)
This publication has 52 references indexed in Scilit:
- Coronary stents: novel developmentsHeart, 2013
- Primary Endpoint Results of the EVOLVE TrialJACC, 2012
- Vascular Cell Adhesion Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen Species and AntioxidantsAntioxidants & Redox Signaling, 2011
- 2-Year Clinical Follow-Up From the Randomized Comparison of Biolimus-Eluting Stents With Biodegradable Polymer and Sirolimus-Eluting Stents With Durable Polymer in Routine Clinical PracticeJACC: Cardiovascular Interventions, 2011
- Paclitaxel/sirolimus combination coated drug-eluting stent: In vitro and in vivo drug release studiesJournal of Pharmaceutical and Biomedical Analysis, 2011
- Drug-Eluting Stents in Preclinical StudiesCirculation: Cardiovascular Interventions, 2008
- In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitroNature Protocols, 2007
- Biliverdin protects against polymicrobial sepsis by modulating inflammatory mediatorsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2006
- Bilirubin decreases NOS2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in ratsThe FASEB Journal, 2005
- Biliverdin Therapy Protects Rat Livers From Ischemia and Reperfusion InjuryHepatology, 2004